Abstract:
BACKGROUND AND OBJECTIVE Evidence on the economic value of rotavirus vaccines in middle-income countries is limited.
We aimed to model the implementation of three vaccines (human rotavirus, live, attenuated, oral vaccine [HRV, 2 doses];
rotavirus vaccine, live, oral, pentavalent [HBRV, 3 doses] and rotavirus vaccine, live attenuated oral, freeze-dried [BRV-PV,
3 doses] presented in 1-dose and 2-dose vials) into the South African National Immunisation Programme.
METHODS Cost and cost-effectiveness analyses were conducted to compare three rotavirus vaccines using a static, deterministic,
population model in children aged <5 years in South Africa from country payer and societal perspectives. Deterministic
and probabilistic sensitivity analyses were conducted to assess the impact of uncertainty in model inputs.
RESULTS The human rotavirus, live, attenuated, oral vaccine (HRV) was associated with cost savings versus HBRV from both
perspectives, and versus BRV-PV 1-dose vial from the societal perspective. In the cost-effectiveness analysis, HRV was estimated
to avoid 1,107 home care rotavirus gastroenteritis (RVGE) events, 247 medical visits, 35 hospitalisations, and 4 RVGErelated
deaths versus HBRV and BRV-PV. This translated to 73 quality-adjusted life years gained. HRV was associated with
lower costs versus HBRV from both payer (−$3.9M) and societal (−$11.5M) perspectives and versus BRV-PV 1-dose vial
from the societal perspective (−$3.8M), dominating those options. HRV was associated with higher costs versus BRV-PV
1-dose vial from the payer perspective and versus BRV-PV 2‑dose vial from both payer and societal perspectives (ICERs:
$51,834, $121,171, and $16,717, respectively), exceeding the assumed cost-effectiveness threshold of 0.5 GDP per capita.
CONCLUSION Vaccination with a 2-dose schedule of HRV may lead to better health outcomes for children in South Africa
compared with the 3-dose schedule rotavirus vaccines.
